New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada

New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada

We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Drs  Kerri Schellenberg, Homira Osman, Erin Beattie, Hanns Lochmüller, Craig Campbell, Jean Mah as well as Stacey Lintern, Maria Masnata, Rhiannon Hicks, Corinne Kagan and Ana Stosic. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research. 

Recognizing the unique challenges of conducting clinical trials in rare diseases, including small patient populations, geographic dispersion, and limited infrastructure, the study identified key barriers across the Canadian landscape. These included burdensome feasibility processes, limited workforce capacity, lack of centralized trial visibility, and fragmented coordination among stakeholders.

In response, the NMD4C Clinical Trial Network developed targeted strategies to address these gaps, including centralized feasibility triage, a national Community of Practice, mentorship, operational support, and alignment with patient and registry infrastructure. These efforts aim to strengthen coordination, support clinical trial personnel, and improve the overall delivery of neuromuscular trials across Canada.

This work presents a practical model for building a more coordinated and sustainable clinical trial ecosystem, with the potential to improve trial readiness and access for individuals living with rare neuromuscular diseases.

Read the Full Publication

New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada

Read next...

CPNG 2026

Zolgensma® Safety Update and CPNG Guidance for Families

The Canadian Pediatric Neuromuscular Group (CPNG) has issued a statement for families regarding recent reports of tumours in children treated with Zolgensma® (onasemnogene abeparvovec) gene therapy for spinal muscular atrophy (SMA). The statement outlines current evidence, considerations for follow-up care, and information for families and healthcare providers.

2026 Trainee Publication of the Year Awardee Spotlight on Jules Granet

Could You Be Our Next Awardee? Meet Jules Granet, NMD4C’s 2026 Publication of the Year Awardee

Nominations are open till by 18 January 2027!
In 2026, Jules Granet, a PhD Candidate at McGill University and trainee in Dr. Natasha Chang’s laboratory received an NMD4C Publication of the Year Award for research investigating how muscle stem cell dysfunction contributes to impaired muscle regeneration in Duchenne muscular dystrophy. Nominate yourself or a neuromuscular colleague whose research, clinical care, leadership, advocacy, or community contributions deserve to be recognized.

Save the date: 8th Ottawa International Conference On Neuromuscular Disease & Biology

Early Bird Registration Now Open: 8th Ottawa International Conference On Neuromuscular Disease & Biology

We are happy to announce that early bird registration is now open for the 8th Ottawa International Conference On Neuromuscular Disease & Biology which will be held on October 14-16, 2027 at the Fairmont Château Laurier in Ottawa, Canada. Now under the leadership of NMD4C Investigators; Dr. Mireille Khacho, Dr. Hanns Lochmuller, Dr. Bernard Jasmin, and Dr. Rashmi Kothary.